{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:05:08Z","timestamp":1792796708159,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00949-5","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T14:26:44Z","timestamp":1746541604000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Disease Modification in Psoriasis: Future Prospects for Long-Term Remission"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1337-3836","authenticated-orcid":false,"given":"David","family":"Ranzinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"2","key":"949_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjd.14500","volume":"175","author":"DM Balak","year":"2016","unstructured":"Balak DM, Fallah Arani S, Hajdarbegovic E, et al. Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. Br J Dermatol. 2016;175(2):250\u201362.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"949_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"6","key":"949_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"949_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359.","journal-title":"Br J Dermatol"},{"issue":"4","key":"949_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jdv.16964","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. 2021;35(4):919\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"949_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000870","volume":"5","author":"LE Burgers","year":"2019","unstructured":"Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis: definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870.","journal-title":"RMD Open"},{"issue":"1","key":"949_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000634","volume":"9","author":"R van Vollenhoven","year":"2022","unstructured":"van Vollenhoven R, Askanase AD, Bomback AS, et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med. 2022;9(1):e000634.","journal-title":"Lupus Sci Med."},{"issue":"5","key":"949_CR8","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1111\/jdv.19652","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Krueger J, Stahle M, et al.\u00a0An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis. J Eur Acad Dermatol Venereol. 2024;38(5):e424\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"949_CR9","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, et al.\u00a0Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320.","journal-title":"J Immunol"},{"issue":"3","key":"949_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"27","key":"949_CR11","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1056\/NEJMc1508234","volume":"373","author":"AR Ahmed","year":"2015","unstructured":"Ahmed AR, Kaveri S, Spigelman Z. Long-term remissions in recalcitrant pemphigus vulgaris. N Engl J Med. 2015;373(27):2693\u20134.","journal-title":"N Engl J Med"},{"issue":"8","key":"949_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"7","key":"949_CR13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/all.14224","volume":"75","author":"M Martini","year":"2020","unstructured":"Martini M, Corsi A, Agolini S, et al. High long-term efficacy of venom immunotherapy after discontinuation. Allergy. 2020;75(7):1793\u20136.","journal-title":"Allergy"},{"issue":"1","key":"949_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"949_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40262-019-00842-5","volume":"59","author":"Y Pang","year":"2020","unstructured":"Pang Y, Khatri A, Suleiman AA, Othman AA.\u00a0Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients. Clin Pharmacokinet. 2020;59(3):311\u201326.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"949_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304\u201315.","journal-title":"Br J Dermatol"},{"key":"949_CR17","doi-asserted-by":"crossref","unstructured":"Bagit A, Maliyar K, Mansour M, et al. Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study. J Eur Acad Dermatol Venereol. 2025;39(5):e410\u2013e412.","DOI":"10.1111\/jdv.20373"},{"issue":"3","key":"949_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"949_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","volume":"136","author":"JG Krueger","year":"2015","unstructured":"Krueger JG, Ferris LK, Menter A, et al.\u00a0Anti\u2013IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116\u201324.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"949_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/jdv.14387","volume":"31","author":"M Masson Regnault","year":"2017","unstructured":"Masson Regnault M, Konstantinou MP, Khemis A, et al.\u00a0Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31(9):1491\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"949_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al.\u00a0The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8 Suppl.","key":"949_CR22","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.jid.2024.06.1116","volume":"144","author":"Y Chen","year":"2024","unstructured":"Chen Y, Angsana J, Yum N, et al. LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. J Investig Dermatol. 2024;144(8 Suppl.):S165.","journal-title":"J Investig Dermatol"},{"issue":"10273","key":"949_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al.\u00a0Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"7","key":"949_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/archderm.142.7.836","volume":"142","author":"SS Yones","year":"2006","unstructured":"Yones SS, Palmer RA, Garibaldinos TT, Hawk JL.\u00a0Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142(7):836\u201342.","journal-title":"Arch Dermatol"},{"issue":"7","key":"949_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1056\/NEJMoa021359","volume":"349","author":"VM Heydendael","year":"2003","unstructured":"Heydendael VM, Spuls PI, Opmeer BC, et al.\u00a0Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"949_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1600-0781.2009.00413.x","volume":"25","author":"S Radakovic","year":"2009","unstructured":"Radakovic S, Seeber A, H\u00f6nigsmann H, Tanew A. Failure of short-term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque-type psoriasis. Photodermatol Photoimmunol Photomed. 2009;25(2):90\u20133.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"949_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, et al.\u00a0Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"949_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40257-023-00801-8","volume":"24","author":"A Aronovich","year":"2023","unstructured":"Aronovich A, Novikov I, Pavlovsky L. Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A sytematic review. Am J Clin Dermatol. 2023;24(6):865\u201373.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"949_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","volume":"136","author":"JB Lerman","year":"2017","unstructured":"Lerman JB, Joshi AA, Chaturvedi A, et al.\u00a0Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263\u201376.","journal-title":"Circulation"},{"issue":"10","key":"949_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jid.2023.02.037","volume":"143","author":"S Piaserico","year":"2023","unstructured":"Piaserico S, Papadavid E, Cecere A, et al.\u00a0Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J Invest Dermatol. 2023;143(10):1929\u201336.e2.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"949_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","volume":"4","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Oikonomou EK, Dey AK, et al.\u00a0Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885\u201391.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"949_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/jdv.16635","volume":"35","author":"G Holzer","year":"2021","unstructured":"Holzer G, Hoke M, Sabeti-Sandor S, et al.\u00a0Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial. J Eur Acad Dermatol Venereol. 2021;35(2):441\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"949_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jdv.19520","volume":"38","author":"K Kridin","year":"2024","unstructured":"Kridin K, Abdelghaffar M, Mruwat N, et al.\u00a0Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? Insights from an international population-based study. J Eur Acad Dermatol Venereol. 2024;38(2):315\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"949_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ced\/llae276","volume":"50","author":"V Shah","year":"2024","unstructured":"Shah V, Larson A, Jafferany M. Exploring the psychological impact of childhood-onset psoriasis: a systematic review. Clin Exp Dermatol. 2024;50(1):29\u201337.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"949_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, et al.\u00a0Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"949_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","volume":"164","author":"RB Warren","year":"2011","unstructured":"Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164(Suppl. 1):1\u201314.","journal-title":"Br J Dermatol"},{"issue":"2","key":"949_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/09546634.2018.1476654","volume":"30","author":"N Salame","year":"2019","unstructured":"Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. J Dermatolog Treat. 2019;30(2):135\u201340.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"949_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjd.17259","volume":"180","author":"F Sampogna","year":"2019","unstructured":"Sampogna F, Puig L, Spuls P, et al.\u00a0Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. Br J Dermatol. 2019;180(2):397\u2013403.","journal-title":"Br J Dermatol"},{"issue":"9","key":"949_CR39","first-page":"1856","volume":"42","author":"YS Patt","year":"2024","unstructured":"Patt YS, Watad A, Giovannini I, et al.\u00a0Risk factors for psoriatic arthritis development in psoriasis patients: myths, pitfalls, and pearls. Clin Exp Rheumatol. 2024;42(9):1856\u201366.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"949_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, et al.\u00a0IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9): e049822.","journal-title":"BMJ Open"},{"issue":"10","key":"949_CR41","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Schakel","year":"2023","unstructured":"Schakel K, Reich K, Asadullah K, et al.\u00a0Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"949_CR42","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, et al.\u00a0Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160(9):953\u201363.","journal-title":"JAMA Dermatol"},{"issue":"3 Suppl.","key":"949_CR43","doi-asserted-by":"publisher","first-page":"AB222","DOI":"10.1016\/j.jaad.2024.07.883","volume":"91","author":"K Sch\u00e4kel","year":"2024","unstructured":"Sch\u00e4kel K, Asadullah K, Pinter A, et al.\u00a050236 GUIDE trial results after withdrawal in part 3: long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms. J Am Acad Dermatol. 2024;91(3 Suppl.):AB222.","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"949_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/ced\/llad329","volume":"49","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Iversen L, Eidsmo L, et al.\u00a0Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies. Clin Exp Dermatol. 2024;49(8):793\u2013800.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"949_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000542344","volume":"241","author":"B Kirby","year":"2024","unstructured":"Kirby B, Chiricozzi A, Gorecki P, et al. Time to loss of disease control following guselkumab withdrawal in relation to initial speed of response: a post hoc analysis of the VOYAGE 2 trial. Dermatology. 2024;241(2):133\u201342.","journal-title":"Dermatology"},{"key":"949_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-981-15-3449-2_8","volume":"1253","author":"S Shao","year":"2020","unstructured":"Shao S, Gudjonsson JE. Epigenetics of psoriasis. Adv Exp Med Biol. 2020;1253:209\u201321.","journal-title":"Adv Exp Med Biol"},{"key":"949_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2017.04.005","volume":"83","author":"E Generali","year":"2017","unstructured":"Generali E, Ceribelli A, Stazi MA, Selmi C.\u00a0Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017;83:51\u201361.","journal-title":"J Autoimmun"},{"key":"949_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaut.2017.04.003","volume":"83","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Yang Y, Chang C, Lu Q.\u00a0The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J Autoimmun. 2017;83:43\u201350.","journal-title":"J Autoimmun"},{"issue":"9","key":"949_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrg1693","volume":"6","author":"L Flintoft","year":"2005","unstructured":"Flintoft L. Identical twins: epigenetics makes the difference. Nat Rev Genet. 2005;6(9):667.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"949_CR50","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jid.2017.11.036","volume":"138","author":"D Verma","year":"2018","unstructured":"Verma D, Ekman AK, Bivik Eding C, Enerback C.\u00a0Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J Invest Dermatol. 2018;138(5):1088\u201393.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"949_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-018-0541-9","volume":"10","author":"A Chandra","year":"2018","unstructured":"Chandra A, Senapati S, Roy S, et al.\u00a0Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin Epigenetics. 2018;10(1):108.","journal-title":"Clin Epigenetics"},{"issue":"5 Suppl.","key":"949_CR52","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.jid.2023.03.838","volume":"143","author":"C Conrad","year":"2023","unstructured":"Conrad C, Gaulis S, Bier K, et al.\u00a0828 Early intervention with secukinumab may affect the establishment of tissue memory in psoriasis: results from a DNA methylation analysis. J Investig Dermatol. 2023;143(5 Suppl.):S142.","journal-title":"J Investig Dermatol"},{"key":"949_CR53","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3389\/fimmu.2019.01525","volume":"10","author":"AEA Surace","year":"2019","unstructured":"Surace AEA, Hedrich CM. The role of epigenetics in autoimmune\/inflammatory disease. Front Immunol. 2019;10:1525.","journal-title":"Front Immunol"},{"issue":"4","key":"949_CR54","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1684\/ejd.2011.1383","volume":"21","author":"P Zhang","year":"2011","unstructured":"Zhang P, Su Y, Zhao M, et al. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol. 2011;21(4):552\u20137.","journal-title":"Eur J Dermatol"},{"key":"949_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699900","volume":"12","author":"J Zeng","year":"2021","unstructured":"Zeng J, Zhang Y, Zhang H, et al.\u00a0RPL22 overexpression promotes psoriasis-like lesion by inducing keratinocytes abnormal biological behavior. Front Immunol. 2021;12: 699900.","journal-title":"Front Immunol"},{"issue":"12","key":"949_CR56","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/exd.13790","volume":"27","author":"MC Ovejero-Benito","year":"2018","unstructured":"Ovejero-Benito MC, Reolid A, Sanchez-Jimenez P, et al.\u00a0Histone modifications associated with biological drug response in moderate-to-severe psoriasis. Exp Dermatol. 2018;27(12):1361\u201371.","journal-title":"Exp Dermatol"},{"issue":"3","key":"949_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jdermsci.2010.03.004","volume":"58","author":"JR Zibert","year":"2010","unstructured":"Zibert JR, L\u00f8vendorf MB, Litman T, et al.\u00a0MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci. 2010;58(3):177\u201385.","journal-title":"J Dermatol Sci"},{"key":"949_CR58","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.2147\/IJN.S441353","volume":"19","author":"Y Han","year":"2024","unstructured":"Han Y, Xi L, Leng F, et al. Topical delivery of microRNA-125b by framework nucleic acids for psoriasis treatment. Int J Nanomedicine. 2024;19:2625\u201338.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"949_CR59","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1684\/ejd.2013.2190","volume":"23","author":"H Hirao","year":"2013","unstructured":"Hirao H, Jinnin M, Ichihara A, et al.\u00a0Detection of hair root miR-19a as a novel diagnostic marker for psoriasis. Eur J Dermatol. 2013;23(6):807\u201311.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"949_CR60","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.jid.2018.02.030","volume":"138","author":"I Gallais S\u00e9r\u00e9zal","year":"2018","unstructured":"Gallais S\u00e9r\u00e9zal I, Classon C, Cheuk S, et al.\u00a0Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138(8):1754\u201363.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"949_CR61","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjd.17748","volume":"181","author":"S Vo","year":"2019","unstructured":"Vo S, Watanabe R, Koguchi-Yoshioka H, et al. CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-naive nonlesional sites of psoriasis possibly in correlation with disease duration. Br J Dermatol. 2019;181(2):410\u20132.","journal-title":"Br J Dermatol"},{"issue":"4","key":"949_CR62","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41590-020-0607-7","volume":"21","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Beura LK, Quarnstrom CF, et al.\u00a0Developmental plasticity allows outside-in immune responses by resident memory T cells. Nat Immunol. 2020;21(4):412\u201321.","journal-title":"Nat Immunol"},{"issue":"7","key":"949_CR63","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","volume":"73","author":"EF Leijten","year":"2021","unstructured":"Leijten EF, van Kempen TS, Olde Nordkamp MA, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"77","key":"949_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254","volume":"7","author":"SK Whitley","year":"2022","unstructured":"Whitley SK, Li M, Kashem SW, et al.\u00a0Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells. Sci Immunol. 2022;7(77): eabq3254.","journal-title":"Sci Immunol."},{"issue":"6","key":"949_CR65","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.coi.2011.08.007","volume":"23","author":"A Peters","year":"2011","unstructured":"Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol. 2011;23(6):702\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"949_CR66","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cell.2015.10.068","volume":"163","author":"C Wang","year":"2015","unstructured":"Wang C, Yosef N, Gaublomme J, et al. CD5L\/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell. 2015;163(6):1413\u201327.","journal-title":"Cell"},{"issue":"12","key":"949_CR67","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/ni1539","volume":"8","author":"MJ McGeachy","year":"2007","unstructured":"McGeachy MJ, Bak-Jensen KS, Chen Y, et al.\u00a0TGF-\u03b2 and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat tImmunol. 2007;8(12):1390\u20137.","journal-title":"Nat tImmunol."},{"key":"949_CR68","doi-asserted-by":"publisher","first-page":"8065147","DOI":"10.1155\/2020\/8065147","volume":"2020","author":"C Aguilar-Flores","year":"2020","unstructured":"Aguilar-Flores C, Castro-Escamilla O, Ortega-Rocha EM, et al.\u00a0Association of pathogenic Th17 cells with the disease severity and its potential implication for biological treatment selection in psoriasis patients. Mediators Inflamm. 2020;2020:8065147.","journal-title":"Mediators Inflamm"},{"issue":"7318","key":"949_CR69","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signalling. Nature. 2010;467(7318):967\u201371.","journal-title":"Nature"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00949-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00949-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:03:06Z","timestamp":1751605386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00949-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00949-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"16 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This research received no specific funding from public, commercial, or non-profit organizations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kilian Eyerich reports speakers fees and\/or honoraria for advisory board membership of the following companies: AbbVie, Almirall, Apogee, Boehringer Ingelheim, BMS, Janssen, Leo, Lilly, Moonlake, Novartis, Sanofi, Sitryx, and UCB. Kilian Eyerich holds shares and is a co-founder of Dermagnostix and Dermagnostix R&D. David Ranzinger has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This study does not contain any personal data that require consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors contributed equally to the conception, design, drafting, and critical revision of the manuscript. Both authors approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}